Mannkind Soars 20.04% on $360M Acquisition of scPharmaceuticals

Mannkind's stock surged 20.04% in pre-market trading on September 2, 2025, driven by significant developments in the company's strategic acquisitions and market positioning.

Mannkind Corporation has announced its intention to acquire scPharmaceuticals for approximately $360 million. This acquisition is aimed at expanding Mannkind's cardiometabolic business, which is expected to accelerate revenue growth and solidify the company's position as a leader in cardiometabolic and lung diseases.

The acquisition of scPharmaceuticals is part of Mannkind's broader strategy to enhance its portfolio and drive long-term growth. The deal includes a cash payment of $5.35 per share, representing a 31% premium over the previous Friday's closing price. This move is seen as a strategic investment to bolster Mannkind's market presence and financial performance.

Leerink Partners has reiterated a Buy rating on Mannkind Corporation, maintaining a price target of $7. This positive outlook is supported by the company's recent acquisitions and its potential for revenue growth. The consensus rating for Mannkind remains a Buy, with no hold or sell ratings, reflecting the market's confidence in the company's future prospects.